GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » Owner Earnings per Share (TTM)

Taisho Pharmaceutical Holdings Co (TSE:4581) Owner Earnings per Share (TTM) : 0.00 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Taisho Pharmaceutical Holdings Co does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.


The historical rank and industry rank for Taisho Pharmaceutical Holdings Co's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Taisho Pharmaceutical Holdings Co was 99.59. The lowest was 23.66. And the median was 39.15.


TSE:4581's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.45
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Taisho Pharmaceutical Holdings Co's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was 円34.99. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円102.55. It's PE Ratio ratio for today is 83.76.

Taisho Pharmaceutical Holdings Co's EPS without NRI for the three months ended in Dec. 2023 was 円36.56. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was 円172.24. It's PE Ratio without NRI ratio for today is 49.87.


Taisho Pharmaceutical Holdings Co Owner Earnings per Share (TTM) Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co Owner Earnings per Share (TTM) Chart

Taisho Pharmaceutical Holdings Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Taisho Pharmaceutical Holdings Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Taisho Pharmaceutical Holdings Co's Owner Earnings per Share (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, Taisho Pharmaceutical Holdings Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taisho Pharmaceutical Holdings Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taisho Pharmaceutical Holdings Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Taisho Pharmaceutical Holdings Co's Price-to-Owner-Earnings falls into.



Taisho Pharmaceutical Holdings Co Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Taisho Pharmaceutical Holdings Co does not have enough data to calculate Owner Earnings per Share (TTM). Please check Wal-Mart Stores Inc, as your reference.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Taisho Pharmaceutical Holdings Co Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Traded in Other Exchanges
Address
3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines